CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
REVENUES:
Grant income	$ 1,225	$ 1,109	$ 1,236	$ 3,346
Royalties from product sales and license fees	86	177	277	463
Subscription and advertisement revenues	376	69	940	700
Sale of research products	1	144	6	331
Total revenues	1,688	1,499	2,459	4,840
Cost of sales	(52)	(58)	(114)	(378)
Gross Profit	1,636	1,441	2,345	4,462
OPERATING EXPENSES:
Research and development	(6,562)	(6,422)	(19,327)	(29,093)
General and administrative	(4,587)	(4,574)	(14,111)	(23,083)
Total operating expenses	(11,149)	(10,996)	(33,438)	(52,176)
Gain on sale of assets	0	0	1,754	0
Loss from operations	(9,513)	(9,555)	(29,339)	(47,714)
OTHER INCOME/(EXPENSES):
Interest expense, net	(10)	(167)	(729)	(513)
Loss on extinguishment of related party convertible debt	(2,799)	0	(2,799)	0
Other income (expenses), net	(143)	(173)	1,202	197
Total other income, net	28,271	38,820	82,894	74,075
INCOME BEFORE INCOME TAXES	18,758	29,265	53,555	26,361
Deferred income tax expense	(4,772)	0	(4,772)	0
NET INCOME	13,986	29,265	48,783	26,361
Net loss attributable to noncontrolling interests	335	1,934	3,175	12,286
NET INCOME ATTRIBUTABLE TO BIOTIME, INC.	$ 14,321	$ 31,199	$ 51,958	$ 38,647
NET INCOME PER COMMON SHARE ATTRIBUTABLE TO BIOTIME, INC.:
BASIC (in dollars per share)	$ 0.12	$ 0.30	$ 0.47	$ 0.40
DILUTED (in dollars per share)	$ 0.12	$ 0.30	$ 0.47	$ 0.39
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	115,288	102,711	110,989	95,484
DILUTED (in shares)	115,298	103,613	111,124	99,073
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment at fair value	$ 34,485	$ 0	$ 39,620	$ 0
Gain on deconsolidation	0	0	71,697	0
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment at fair value	(3,262)	40,015	(26,097)	26,532
Gain on deconsolidation	0	0	0	49,048
Ascendance Biotechnology, Inc. [Member]
OTHER INCOME/(EXPENSES):
BioTime's share of losses in equity method investment	$ 0	$ (855)	$ 0	$ (1,189)